Merck & Co is a general drug manufacturer company located in New Jersey, United States, which is part of the Healthcare sector, and is traded under the ticker MRK on the NYSE exchange.
Merck & Co stock last closed at $101.88, down 0.43% from the previous day, and has decreased 0.94% in one year. It has underperformed other stocks in the Drug Manufacturers - General industry by 0.21 percentage points. Merck & Co stock is currently +3.33% from its 52-week low of $98.60, and -24.33% from its 52-week high of $134.63.
As of Nov 1, 2024, there are 2.53B MRK shares outstanding. The market cap of MRK is $258.25B. In the past 24 hours, 9.21M MRK shares were traded.
How to Buy Merck & Co Stock
Not sure how to invest in Merck & Co stock? Here's how.
Decide where to buy Merck & Co stock: You need to choose an online brokerage, but don't worry - we've researched dozens of online stock brokerages and apps to help you decide where to buy Merck & Co stock.
Create a brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've identified.
Put funds into your brokerage account: Choose your method of payment and add your information.
Analyze Merck & Co stock: The Merck & Co ticker symbol is MRK. Is Merck & Co stock a good investment? Should you buy shares of MRK? How do MRK's underlying business fundamentals look? Do top analysts think Merck & Co is a good buy? Why has MRK's stock price moved recently? (Hint: Our stock market analysis website can help you figure out if MRK is a good stock to buy).
Make your MRK trade: Decide if you will purchase MRK shares at the current market price or use a limit order to purchase MRK shares at a given price.
Track your MRK position: Create a watchlist to watch your new investment in Merck & Co shares.
Step 1: Decide where to buy Merck & Co stock
You need a brokerage account in order to access the NYSE market and buy MRK shares.
A brokerage account allows you to buy and sell a number of investments, such as stocks, bonds, mutual funds, and ETFs.
Our favorite brokerage: eToro
We believe that eToro is the best brokerage. Here's why:
You can invest in stocks with 0% commissions: Invest without commissions.
Buy fractional shares: Even if you don't have the money to buy a full share, you can still purchase the stock.
Access to global markets: From Tech to Industrials, New York to Hong Kong — you can fill your portfolio with stocks from the world's top exchanges.
Social investing: eToro boasts a community with more than 20 million users around the world. Talk to, learn from, and copy the crypto trades of other investors.
Security: eToro is a regulated and licensed brokerage platform.
Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your stock purchase by creating an account with eToro today.
eToro securities trading is offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency is offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. https://www.wallstreetzen.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD.
Step 2: Create a brokerage account
Now that you've chosen the right brokerage, you need to fill out some personal details so you are able to invest in MRK today.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
Step 4: Analyze Merck & Co stock
After you have figured out the best place to buy Merck & Co stock, it's critical to research their stock before you buy, so you can comprehend the risk and opportunity.
Merck & Co Numbers
MRK Price
$101.88
1w %
-2.02%
1y %
-0.94%
5y %
19.94%
P/E
18.83x
P/B
5.93x
P/S
4.13x
PEG
0.73x
Revenue
$62.48B
Earnings
$13.74B
Fore. Rev. Growth
4.54%
Fore. Earn. Growth
25.7%
Market Cap
$258.25B
Next Earnings
N/A
Next Dividend
N/A
MRK Due Diligence Checks
WallStreetZen was built to help part-time investors do more accurate fundamental analysis quickly.
You can view all of the due diligence checks on MRK's stock page.
Is MRK stock undervalued?
You can use a variety of different financial metrics, analyses, models, and charts to gauge MRK's true value.
Using relative valuations ratios:
MRK could be undervalued based on its P/E ratio of 18.83x, relative to Drug Manufacturers - General industry P/E ratio of 43.75x
MRK could be undervalued based on its P/B ratio of 5.93x, relative to Drug Manufacturers - General industry P/B ratio of 6.44x
MRK could be undervalued based on its PEG ratio of 0.73x
MRK earnings of $16.47B is not enough to cover its interest payments.
MRK's operating cash flow of $16.69B allows it to safely service it's debt of $37.79B.
Total MRK debt is lower than 5 years ago, relative to shareholder equity.
There are more short-term assets than short-term liabilities on the MRK balance sheet.
MRK profit margin has gone up from 5.3% to 22% in the past year.
Negative Health Checks:
There are more long-term liabilities than short-term assets on the MRK balance sheet.
MRK has a relatively high debt to equity ratio of 1.58.
Is Merck & Co stock a Buy, Hold, or Sell, according to analysts?
Out of 9 sell side analysts who give ratings on MRK, the consensus analyst rating on Merck & Co is a Strong Buy
It's important to note that analyst ratings are not stock recommendations, nor are they financial advice.
Latest MRK Analyst Ratings
Colin Bristow, a bottom 8% analyst from UBS maintains MRK with a strong buy rating and lowers their MRK price target from $142.00 to $136.00, on Oct 9, 2024.
Robyn Karnauskas, a bottom 3% analyst from Truist Securities maintains MRK with a strong buy rating and lowers their MRK price target from $143.00 to $132.00, on Oct 9, 2024.
Carter Gould, a top 13% analyst from Barclays maintains MRK with a strong buy rating and lowers their MRK price target from $142.00 to $140.00, on Oct 7, 2024.
Louise Chen, a top 16% analyst from Cantor Fitzgerald reiterates MRK with a strong buy rating and maintains their MRK price target from $155.00 to $155.00, on Oct 3, 2024.
Geoff Meacham, a bottom 4% analyst from Bank of America maintains MRK with a strong buy rating and lowers their MRK price target from $150.00 to $145.00, on Jul 31, 2024.
Last year, MRK earnings were $13.74B. Over the last five year, MRK's earnings have increased by 8.49% per year. This was faster than the Drug Manufacturers - General industry average of 1.95%.
Last year, MRK revenue was $62.48B. Over the past 5 year, MRK's revenue has grown by 7.09% per year. This was slower than the Drug Manufacturers - General industry average of 8.15%.
Merck & Co pays a dividend of 3.02%, compared to the Drug Manufacturers - General industry's average dividend yield of 3.31%. If you owned $1,000 of MRK stock, you would have received $30.23 last year.
Merck & Co dividend payments have consistently grown over the past decade and have remained stable.
One of the biggest reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to find out what other investors have to say.
Step 5: Make your MRK trade
There are two main options:
Market order: A market order is an order to buy or sell a stock at the best possible price. Market orders are usually the best for newer investors.
Limit order: A limit order lets you buy or sell a stock at a specific price (or better). If you want to ensure you're buying or selling at a specific price limit, place a limit order.
Click the Open button and eToro will place the order.
If you need more help buying stocks on eToro, watch the helpful video below:
How much does it cost to buy one Merck & Co share?
As of Nov 1, 2024, it costs $101.88 to buy one share of Merck & Co stock.
Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $10, you can buy 0.098 shares of MRK.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.